EQL Pharma (EQL) CMD 2025 summary

Strategic ambitions and financial targets

• New five-year plan targets 30% average annual sales growth, aiming to surpass SEK 1 billion in revenue by 2028/2029, with a focus on organic growth and selective M&A as a supplement.

• Profitability goal is to stabilize EBITDA margin above 25% by the end of the period, prioritizing sales growth over margin in the short term if needed.

• Leverage ratio target is below 2.5, with a temporary ceiling of 4.0 for opportunistic acquisitions or strategic investments.

• Growth will be driven by pipeline launches, branded products (Mellozzan and Memprex), specialty generics, and targeted acquisitions.

• Expansion outside the Nordics is not a significant contributor to the current five-year plan but is a focus for long-term growth, with geographic expansion into non-Nordic EU markets underway.

Business model and operational focus

• Operates an asset-light model, outsourcing manufacturing and distribution while focusing in-house on product identification, regulatory, and project management.

• Maintains a 70% historical success rate in product launches, with a strategy to fail fast and minimize sunk costs.

• Capital allocation emphasizes rapid CapEx turnaround, with most projects achieving payback within two years and an average ROCE of 20%.

• OpEx as a percentage of sales has been reduced from 35% to 21%, with further efficiency gains targeted.

• Sustainability is integrated into the business model, addressing pricing, health equity, and environmental standards, aiming to deliver affordable, accessible healthcare.

Product and market development

• Portfolio includes 40 marketed products and 40 in the pipeline, with launches planned across pharmacy, hospital, branded, and specialty generics segments.

• Branded products Mellozzan (for pediatric ADHD-related insomnia) and Memprex (for recurrent urinary tract infections) are expanding in Europe via B2B partnerships, leveraging unmet needs and strong value propositions, with Mellozzan achieving a 59% CAGR and Memprex 185% CAGR.

• Specialty generics target non-interchangeable products with higher margins (60–80%) and longer market build-up, supported by new hires in medical and commercial roles.

• Hospital segment growth is on track, with successful tender participation and a robust pipeline.

• Focuses on products with minimal generic competition post-patent expiry, enabling higher price retention and superior margin profiles.